Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityBIOL / Biolase, Inc. (090911108)
President and CEOFlynn Harold C Jr.
IndustryDental Equipment and Supplies
Institutional Owners11
Institutional Shares1,849,114 - 8.98%
Common Shares Outstanding20,596,901 shares (as of 2018-06-30)
Institutional Value$ 2,490,000 USD

Institutional Stock Ownership and Shareholders()

Biolase, Inc. (NASDAQ:BIOL) has 11 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,849,114 shares. Largest shareholders include BlackRock Institutional Trust Company, N.A., Birchview Capital, LP, Princeton Capital Management Inc, BlackRock Fund Advisors, Northern Trust Corp, Teton Advisors, Inc., Gamco Investors, Inc. Et Al, BlackRock Advisors LLC, Bank of New York Mellon Corp, and BlackRock Investment Management, LLC.
Biolase, Inc. (NASDAQ:BIOL) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR VANGUARD GROUP INC 1,460,143 0 -100.00 595 0 -100.00
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 89,548 0 -100.00 36 0 -100.00
2018-08-14 13F-HR GOLDMAN SACHS GROUP INC 24,338 0 -100.00 10 0 -100.00
2018-08-10 13F-HR GAMCO INVESTORS, INC. ET AL 134,601 20,000 -85.14 55 24 -56.36
2018-08-14 13F-HR Lido Advisors, LLC 12,322 0 -100.00 5 0 -100.00
2018-07-31 13F-HR Tarbox Group, Inc. 79,484 0 -100.00 32 0 -100.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 6,170 6,170 0.00 11 9 -18.18
2018-08-06 13F-HR Bank of New York Mellon Corp 66,438 11,062 -83.35 27 13 -51.85
2018-08-14 13F-HR MORGAN STANLEY 76,322 0 -100.00 31 0 -100.00
2018-07-20 13F-HR Creative Planning 14,275 0 -100.00 6 0 -100.00
2018-08-02 13F-HR HUDSON CANYON INVESTMENT COUNSELORS LLC 30,150 0 -100.00 12 0 -100.00
2018-08-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 2,844 2,844 0.00 1 1 0.00
2018-08-07 13F-HR IFP Advisors, Inc 10,307 0 -100.00 4 0 -100.00
2018-08-14 13F-HR ROYAL BANK OF CANADA 1,097 0 -100.00 0 0
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 38,326 0 -100.00 16 0 -100.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 1,374,269 1,374,269 0.00 2,405 1,924 -20.00
2018-08-14 13F-HR UBS Group AG 44,226 0 -100.00 18 0 -100.00
2018-08-10 13F-HR UNITED SERVICES AUTOMOBILE ASSOCIATION 11,125 0 -100.00 5 0 -100.00
2018-08-13 13F-HR Advisor Group, Inc. 366 0 -100.00 0 0
2018-08-14 13F-HR GUGGENHEIM CAPITAL LLC 21,958 0 -100.00 9 0 -100.00
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 242 0 -100.00 0 0
2018-08-14 13F-HR NORTHERN TRUST CORP 113,675 32,060 -71.80 46 39 -15.22
2018-08-10 13F-HR GABELLI FUNDS LLC 94,220 0 -100.00 38 0 -100.00
2018-08-10 13F-HR Teton Advisors, Inc. 459,606 30,000 -93.47 187 36 -80.75
2018-08-14 13F-HR STATE STREET CORP 25,076 0 -100.00 10 0 -100.00
2018-02-16 13F-HR/A Commonwealth Equity Services, Inc 12,634 0 -100.00 12 0 -100.00
2018-08-03 13F-HR WEDBUSH SECURITIES INC 10,312 0 -100.00 4 0 -100.00
2018-07-24 13F-HR Trellus Management Company, LLC 375,028 0 -100.00 152 0 -100.00
2018-08-02 13F-HR Birchview Capital, LP 1,285,903 136,180 -89.41 522 165 -68.39
2018-08-14 13F-HR ORACLE INVESTMENT MANAGEMENT INC 30,866,262 0 -100.00 12,532 0 -100.00
2018-08-14 13F-HR DEUTSCHE BANK AG\ 57 0 -100.00 0 0
2017-07-31 13F-HR PRINCETON CAPITAL MANAGEMENT INC 125,925 121,130 -3.81 170 117 -31.18
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 206,201 0 -100.00 84 0 -100.00
2018-08-15 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 167,116 0 -100.00 68 0 -100.00
2017-02-10 13F-HR BlackRock Fund Advisors 100,652 104,274 3.60 176 146 -17.05
2017-02-10 13F-HR BlackRock Advisors LLC 11,125 11,125 0.00 19 16 -15.79
2018-08-09 13F-HR BlackRock Inc. 1,423,686 0 -100.00 578 0 -100.00

Related Articles

REPH: Recro Pharma Analysis and Research Report

23h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

Biolase, Inc. (BIOL) CEO Todd Norbe on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
Ladies and gentlemen, thank you for standing by. And welcome to the BIOLASE conference call to discuss the Company's results for its Second Quarter ending June 30, 2018. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the call will be opened for questions. [Operator Instructions] For the benefit of those who maybe listening to the conference call replay, this call was held and recorded on August 8, 2018. (1-0)

Biolase's (BIOL) CEO John Beaver on Q1 2018 Results - Earnings Call Transcript

2018-05-02 seekingalpha
Ladies and gentlemen, thank you for standing by and welcome to the BIOLASE conference call to discuss the Company’s results for its First Quarter and ending March 31, 2018. During today’s presentation, all parties will be in a listen-only mode. Following the presentation, the call will be opened for questions. [Operator Instructions] For the benefit of those who maybe listening to the conference call replay, this call was held and recorded on May 2, 2018. (5-1)

Biolase's (BIOL) CEO Harold Flynn on Q4 2017 Results - Earnings Call Transcript

2018-03-15 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the BIOLASE conference call to discuss the company’s results for its Fourth Quarter and Year Ended December 31, 2017. During today’s presentation, all parties will be in a listen-only mode. Following the presentation, the call will be opened for questions. [Operator Instructions] For the benefit of those who maybe listening to the conference call replay, this call was held and recorded on March 14, 2017. (5-1)

CUSIP: 090911108